Loading organizations...
Key people at Zafgen.
Zafgen was founded in 2005 by Avi Goldberg (Co-Founder, Board Member).
Zafgen was a biopharmaceutical company developing novel therapeutic candidates for severe and complex forms of obesity. Its research centered on directly targeting fat metabolism with investigational compounds such as beloranib and ZGN-433. The company’s technical approach advanced small molecule therapies through clinical development to address unmet needs in obesity management.
Founded in 2005, Zafgen emerged from the insight that existing obesity treatments often failed to address underlying biological mechanisms of fat accumulation. The company aimed to develop therapies beyond appetite suppression, focusing instead on cellular pathways controlling fat synthesis and storage to restore metabolic balance.
Zafgen sought to serve individuals suffering from severe obesity, including hypothalamic-injury-associated obesity, where conventional treatments were largely ineffective. The company’s vision was to significantly improve patient health by providing pharmacological interventions that enabled a fundamental shift towards a leaner, healthier physiological state.
Key people at Zafgen.
Zafgen was founded in 2005 by Avi Goldberg (Co-Founder, Board Member).
Zafgen was a clinical-stage biopharmaceutical company developing novel therapies based on its proprietary MetAP2 biology platform, initially targeting obesity, metabolic diseases, and later rare disorders like Prader-Willi Syndrome (PWS) and hypothalamic obesity.[1][2][3][4] It served patients with severe metabolic conditions and rare genetic diseases, addressing unmet needs in weight management and intracellular protein deficiencies where traditional treatments failed, such as delivering frataxin for Friedreich’s ataxia post-merger.[1][3] Growth momentum included early clinical proof-of-concept in obesity and PWS by 2012, a public listing on Nasdaq (ZFGN), and pipeline expansion despite setbacks like safety issues with beloranib in 2016, culminating in a 2020 merger with Chondrial Therapeutics to form Larimar Therapeutics (Nasdaq: LRMR), now advancing CTI-1601 in Phase 1 for Friedreich’s ataxia.[1][2][3]
Zafgen emerged around 2006-2012, evolving from Xeno Biosciences, a private drug development firm focused on obesity and metabolic diseases, with a pivot to orphan indications like PWS recognized as a core strategy by 2012.[3][4] Key figures included founders leveraging MetAP2 insights, with leadership strengthening over time: Tom Hughes as President and CSO, Jeff Hatfield (ex-CEO of Vitae Pharmaceuticals) as CEO in 2018, Frank Thomas (ex-CFO/COO of AMAG) for financial expertise pre-IPO, and Brian McVeigh (ex-GSK BD VP) as CBO.[3] Pivotal moments were initial clinical proof-of-concept in obesity post-2010, a 2016 safety halt on beloranib due to thrombotic events, strategic regrouping toward PWS with ZGN-1258 and liver-specific programs, and the 2020 merger enabling public trading as Larimar.[1][3][4]
Zafgen rode the biotech trend of MetAP2 inhibition for metabolic and rare diseases, capitalizing on timing post-2010 proof-of-concept when obesity therapeutics faced high failure rates, and orphan drugs gained traction via FDA designations (e.g., Rare Pediatric, Fast Track, Orphan for CTI-1601).[1][3] Market forces favoring it included rising demand for intracellular protein replacement in genetic diseases like Friedreich’s ataxia (no approved treatments) and PWS, amid a biotech shift to precision rare disease platforms post-2016 safety pivots.[1][3] It influenced the ecosystem by validating MetAP2 for hard-to-treat indications, paving the way for Larimar's public transition and broader fusion protein applications, while exemplifying resilient biotech evolution from obesity to orphan focus.[1][2][3]
Larimar Therapeutics, Zafgen's successor, advances CTI-1601 through Phase 1 toward potential first frataxin therapy for Friedreich’s ataxia, with plans to expand the platform to other rare diseases deficient in intracellular compounds.[1] Trends like accelerated orphan drug approvals and gene-agnostic protein delivery will shape its path, potentially amplifying influence via new investors and leadership. As Zafgen's MetAP2 legacy endures in Larimar's public mission, it underscores biotech's patient-driven adaptability from metabolic setbacks to rare disease breakthroughs.
